These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 37375783)
1. Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective. Pandey S; Mangmool S; Parichatikanond W Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375783 [TBL] [Abstract][Full Text] [Related]
2. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Ban K; Noyan-Ashraf MH; Hoefer J; Bolz SS; Drucker DJ; Husain M Circulation; 2008 May; 117(18):2340-50. PubMed ID: 18427132 [TBL] [Abstract][Full Text] [Related]
3. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Rowlands J; Heng J; Newsholme P; Carlessi R Front Endocrinol (Lausanne); 2018; 9():672. PubMed ID: 30532733 [TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells. Zhang M; Robitaille M; Showalter AD; Huang X; Liu Y; Bhattacharjee A; Willard FS; Han J; Froese S; Wei L; Gaisano HY; Angers S; Sloop KW; Dai FF; Wheeler MB Mol Cell Proteomics; 2014 Nov; 13(11):3049-62. PubMed ID: 25044020 [TBL] [Abstract][Full Text] [Related]
6. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Lee YS; Jun HS Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094 [TBL] [Abstract][Full Text] [Related]
7. Exendin-4 inhibits structural remodeling and improves Ca Chen J; Wang D; Wang F; Shi S; Chen Y; Yang B; Tang Y; Huang C Peptides; 2017 Apr; 90():69-77. PubMed ID: 28242257 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction. McLean BA; Wong CK; Kabir MG; Drucker DJ Mol Metab; 2022 Dec; 66():101641. PubMed ID: 36396031 [TBL] [Abstract][Full Text] [Related]
10. Suppression of Long Non-Coding RNA LINC00652 Restores Sevoflurane-Induced Cardioprotection Against Myocardial Ischemia-Reperfusion Injury by Targeting GLP-1R Through the cAMP/PKA Pathway in Mice. Zhang SB; Liu TJ; Pu GH; Li BY; Gao XZ; Han XL Cell Physiol Biochem; 2018; 49(4):1476-1491. PubMed ID: 30205407 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
12. Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic beta cells. Roger B; Papin J; Vacher P; Raoux M; Mulot A; Dubois M; Kerr-Conte J; Voy BH; Pattou F; Charpentier G; Jonas JC; Moustaïd-Moussa N; Lang J Diabetologia; 2011 Feb; 54(2):390-402. PubMed ID: 21046358 [TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism. Al Batran R; Almutairi M; Ussher JR Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Doyle ME; Egan JM Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374 [TBL] [Abstract][Full Text] [Related]
16. GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca Ramracheya R; Chapman C; Chibalina M; Dou H; Miranda C; González A; Moritoh Y; Shigeto M; Zhang Q; Braun M; Clark A; Johnson PR; Rorsman P; Briant LJB Physiol Rep; 2018 Sep; 6(17):e13852. PubMed ID: 30187652 [TBL] [Abstract][Full Text] [Related]
17. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Maida A; Lovshin JA; Baggio LL; Drucker DJ Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601 [TBL] [Abstract][Full Text] [Related]
18. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940 [TBL] [Abstract][Full Text] [Related]
19. PET of glucagonlike peptide receptor upregulation after myocardial ischemia or reperfusion injury. Gao H; Kiesewetter DO; Zhang X; Huang X; Guo N; Lang L; Hida N; Wang H; Wang H; Cao F; Niu G; Chen X J Nucl Med; 2012 Dec; 53(12):1960-8. PubMed ID: 23139087 [TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Wang D; Luo P; Wang Y; Li W; Wang C; Sun D; Zhang R; Su T; Ma X; Zeng C; Wang H; Ren J; Cao F Diabetes; 2013 May; 62(5):1697-708. PubMed ID: 23364453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]